Crunch Time For Glenmark’s US Innovation Arm, Founding CEO To Exit
Executive Summary
Glenmark’s spin-out innovation arm, Ichnos, faces a crucial year of effort to partner out certain potential first-in-class therapeutics for autoimmune diseases and also to advance its oncology pipeline. Meanwhile, CEO and ex-Gilead executive Alessandro Riva is moving on.
You may also be interested in...
Lupin Seeks Partners For Biosimilars And Oncology Research
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.
Lupin Seeks Partners For Biosimilars, Oncology Research
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.
Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.